Search Results for: THERAPEUTIC FOCUS Targeted Payload Therapies

Articles

- PLATFORM TECHNOLOGY – ​​The 3DNA® Platform for Targeted Drug Delivery

Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.

- 8/29/2012

Synergy Pharmaceuticals Acquires BMS Drug Synergy Pharmaceuticals Inc. recently announced it has signed an Asset Purchase Agreement with Bristol-Myers Squibb...

- SPECIAL FEATURE – Platform Technologies: Not Just for Big Pharma

Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.

- 5/23/2012

Agilent to Acquire Cancer Diagnostic Company for $2.2 Billion Agilent Technologies Inc. and EQT, the Sweden-based private equity group, recently...

- NANOTECHNOLOGY MARKET – Nanotechnology Markets in Healthcare & Medicine

Kevin James, Jackson Highsmith, and Paul Evers report the global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate of 22%. The biggest increase will come in the area of drug delivery systems.

- 3/13/2012

Aegerion Pharmaceuticals Submits US & EU Marketing Applications Aegerion Pharmaceuticals, Inc. recently announced it has submitted an NDA to the...

- 12/5/2012

Curis Announces Several Major Announcements Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group,...